GC Biopharma Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

GC Biopharma ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 1.06%.

Wichtige Informationen

1.1%

Dividendenausschüttung

n/a

Rückkaufsrendite

Gesamte Aktionärsrendite	n/a
Zukünftige Dividendenrendite	1.1%
Wachstum der Dividende	6.6%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	₩1.500k
Ausschüttungsquote	-91%

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Nov 19

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Nov 07

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Während die Dividendenzahlungen stabil waren, zahlt A006280 seit weniger als 10 Jahren eine Dividende.

Wachsende Dividende: A006280 zahlt erst seit 8 Jahren eine Dividende, und seither sind die Zahlungen zurückgegangen.

Dividendenrendite im Vergleich zum Markt

GC Biopharma Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von A006280 im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (A006280)	1.1%
Untere 25 % des Marktes (KR)	1.2%
Markt Top 25 % (KR)	3.9%
Branchendurchschnitt (Biotechs)	0.5%
Analystenprognose (A006280) (bis zu 3 Jahre)	1.1%

Bemerkenswerte Dividende: A006280Die Dividende des Unternehmens (1.06%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt KR (1.22%) nicht bemerkenswert.

Hohe Dividende: A006280Die Dividende des Unternehmens (1.06%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt KR (3.94%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: A006280 zahlt eine Dividende, aber das Unternehmen ist unrentabel.

Barausschüttung an die Aktionäre

Cashflow-Deckung: A006280 zahlt eine Dividende, aber das Unternehmen hat keinen freien Cashflow.

GC Biopharma Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Upcoming dividend of ₩1,750 per share at 1.4% yield

Upcoming dividend of ₩2,000 per share

Upcoming dividend of ₩1,500 per share

Upcoming Dividend of ₩1,000 Per Share

Recent updates

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

GC Biopharma USA Names Sean Zam as Head of Sales and Marketing

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

New 90-day high: ₩505,000

GC Pharma and Clinigen K.K. Announces Marketing Approval for Hunterase ICV Injection 15 mg

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

New 90-day high: ₩475,000

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Upcoming Dividend of ₩1,000 Per Share

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?